Department of Internal Medicine, Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington, KY; Charles and Jane Park Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX; Department of Internal Medicine, Division of Nephrology, University of Alabama at Birmingam, Birmingham, AL.
Department of Internal Medicine, Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington, KY.
Am J Kidney Dis. 2023 Jan;81(1):36-47. doi: 10.1053/j.ajkd.2022.06.004. Epub 2022 Jul 19.
RATIONALE & OBJECTIVE: Risk prediction tools for assisting acute kidney injury (AKI) management have focused on AKI onset but have infrequently addressed kidney recovery. We developed clinical models for risk stratification of mortality and major adverse kidney events (MAKE) in critically ill patients with incident AKI.
Multicenter cohort study.
SETTING & PARTICIPANTS: 9,587 adult patients admitted to heterogeneous intensive care units (ICUs; March 2009 to February 2017) who experienced AKI within the first 3 days of their ICU stays.
Multimodal clinical data consisting of 71 features collected in the first 3 days of ICU stay.
(1) Hospital mortality and (2) MAKE, defined as the composite of death during hospitalization or within 120 days of discharge, receipt of kidney replacement therapy in the last 48 hours of hospital stay, initiation of maintenance kidney replacement therapy within 120 days, or a ≥50% decrease in estimated glomerular filtration rate from baseline to 120 days from hospital discharge.
Four machine-learning algorithms (logistic regression, random forest, support vector machine, and extreme gradient boosting) and the SHAP (Shapley Additive Explanations) framework were used for feature selection and interpretation. Model performance was evaluated by 10-fold cross-validation and external validation.
One developed model including 15 features outperformed the SOFA (Sequential Organ Failure Assessment) score for the prediction of hospital mortality, with areas under the curve of 0.79 (95% CI, 0.79-0.80) and 0.71 (95% CI, 0.71-0.71) in the development cohort and 0.74 (95% CI, 0.73-0.74) and 0.71 (95% CI, 0.71-0.71) in the validation cohort (P < 0.001 for both). A second developed model including 14 features outperformed KDIGO (Kidney Disease: Improving Global Outcomes) AKI severity staging for the prediction of MAKE: 0.78 (95% CI, 0.78-0.78) versus 0.66 (95% CI, 0.66-0.66) in the development cohort and 0.73 (95% CI, 0.72-0.74) versus 0.67 (95% CI, 0.67-0.67) in the validation cohort (P < 0.001 for both).
The models are applicable only to critically ill adult patients with incident AKI within the first 3 days of an ICU stay.
The reported clinical models exhibited better performance for mortality and kidney recovery prediction than standard scoring tools commonly used in critically ill patients with AKI in the ICU. Additional validation is needed to support the utility and implementation of these models.
PLAIN-LANGUAGE SUMMARY: Acute kidney injury (AKI) occurs commonly in critically ill patients admitted to the intensive care unit (ICU) and is associated with high morbidity and mortality rates. Prediction of mortality and recovery after an episode of AKI may assist bedside decision making. In this report, we describe the development and validation of a clinical model using data from the first 3 days of an ICU stay to predict hospital mortality and major adverse kidney events occurring as long as 120 days after hospital discharge among critically ill adult patients who experienced AKI within the first 3 days of an ICU stay. The proposed clinical models exhibited good performance for outcome prediction and, if further validated, could enable risk stratification for timely interventions that promote kidney recovery.
帮助急性肾损伤 (AKI) 管理的风险预测工具主要关注 AKI 的发病,但很少涉及肾脏恢复。我们开发了用于危重症 AKI 患者发生 AKI 后死亡和主要不良肾脏事件 (MAKE) 风险分层的临床模型。
多中心队列研究。
9587 名成年患者,入住异质性重症监护病房 (ICU);2009 年 3 月至 2017 年 2 月期间,入住 ICU 后前 3 天发生 AKI。
包含 ICU 入住前 3 天内采集的 71 个特征的多模态临床数据。
(1) 住院死亡率和 (2) MAKE,定义为住院期间或出院后 120 天内死亡、住院最后 48 小时内接受肾脏替代治疗、出院后 120 天内开始维持性肾脏替代治疗或估计肾小球滤过率从基线下降≥50%。
使用逻辑回归、随机森林、支持向量机和极端梯度提升等 4 种机器学习算法和 SHAP (Shapley Additive Explanations) 框架进行特征选择和解释。通过 10 折交叉验证和外部验证评估模型性能。
包括 15 个特征的一个开发模型在预测住院死亡率方面优于 SOFA (Sequential Organ Failure Assessment) 评分,在开发队列中的曲线下面积分别为 0.79(95%CI,0.79-0.80)和 0.71(95%CI,0.71-0.71),在验证队列中的面积分别为 0.74(95%CI,0.73-0.74)和 0.71(95%CI,0.71-0.71)(均 P<0.001)。包括 14 个特征的第二个开发模型在预测 MAKE 方面优于 KDIGO (Kidney Disease: Improving Global Outcomes) AKI 严重程度分期:在开发队列中为 0.78(95%CI,0.78-0.78)与 0.66(95%CI,0.66-0.66),在验证队列中为 0.73(95%CI,0.72-0.74)与 0.67(95%CI,0.67-0.67)(均 P<0.001)。
该模型仅适用于入住 ICU 后前 3 天内发生 AKI 的危重症成年患者。
与 ICU 中 AKI 患者常用的标准评分工具相比,所报告的临床模型在死亡率和肾脏恢复预测方面表现出更好的性能。需要进一步验证以支持这些模型的实用性和实施。